Efficacy of sulbactam-ampicillin in an induced Pasteurella haemolytica pneumonia model in calves.
Therapeutic efficacy of sulbactam, a beta-lactamase inhibitor, in combination with ampicillin was evaluated in an ampicillin-resistant Pasteurella haemolytica pneumonia model in cattle, using an IV agar emboli method of infection. Groups of cattle given vehicle (group 1, n = 19) or ampicillin (group 2, n = 8) had 74% and 50% mortality, respectively, whereas group 3 (n = 11) given sulbactam-ampicillin had no mortality. Morbidities were 100% in groups 1 and 2 and 27% in group 3. Retrospectively, mortalities and morbidities were significantly (P less than 0.001) lower for group 3 given sulbactam-ampicillin when compared with those in groups 1 and 2 given vehicle or ampicillin, respectively. Evidence of embolic pneumonic pasteurellosis was observed histologically.
Animal Health Research Department, Pfizer Central Research, Terre Haute, IN 47808.
D O
DO
Farrington
J A
JA
Jackson
O E
OE
Bentley
H J
HJ
Barnes
D000667:Ampicillin / Q000008:administration & dosage*; D000668:Ampicillin Resistance; D000818:Animals; D002417:Cattle; D002418:Cattle Diseases / Q000188:drug therapy*; D004338:Drug Combinations; D004352:Drug Resistance, Microbial; D004357:Drug Synergism; D007273:Injections, Intramuscular; D010326:Pasteurella Infections / Q000188:drug therapy / Q000662:veterinary*; D011014:Pneumonia / Q000188:drug therapy / Q000662:veterinary*; D013407:Sulbactam / Q000008:administration & dosage*
D004338:Drug Combinations; D000667:Ampicillin; D013407:Sulbactam